IL4 and Allergy: However, rs2243250 (IL-4) exhibited a trend toward reduced allergy risk in the dominant model (TT vs. TC+CC: adjusted OR = 0.59, 95% CI: 0.34–1.03, p = 0.062) (Table 3).